SEPN — Septerna, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1984086 ·
Last close
$37.77
Market Cap
$1.76B
52W High
$51.10
52W Low
$16.65
ADV30
349,460
Next earnings
2026-11-09
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 26,746,000 | — | -16,836,000 | -13,034,000 | 566,737,000 | 84,662,000 | 180,016,000 |
| Mar 2026 | 26,523,000 | — | -13,300,000 | -8,637,000 | 569,688,000 | 71,605,000 | 191,230,000 |
| Dec 2025 | 24,118,000 | — | -16,023,000 | -10,738,000 | 596,187,000 | 120,722,000 | 214,261,000 |
| Sep 2025 | 21,495,000 | — | -9,886,000 | 8,173,000 | 606,653,000 | 319,989,000 | 217,922,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$107,899,000
Investing CF
$-248,295,000
Financing CF
$1,956,000
CapEx
$-968,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-0.81
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-175,890,000
Inventory
—
Receivables
$14,290,000
ST Investments
$275,796,000
EBIT TTM
$-68,187,000
Pretax Income TTM
$-35,691,000
Interest Exp TTM
—
Analysts
9
Yahoo Snapshot (yfinance, live)
Total Revenue
$98,882,000
EBITDA
$-54,395,000
Free Cash Flow
$29,544,876
Enterprise Value
$1,447,752,192
Total Cash
$372,321,984
Total Debt
$22,545,000
Shares Out
46,676,947
Trailing EPS
$-0.53
Book Value
$8.47
ROE
-6.3%
ROA
-7.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 45,951,000 | -80,797,000 | -48,879,000 | 596,187,000 | 214,261,000 | 381,926,000 | 110,189,000 |
| Dec 2024 | 1,075,000 | -80,823,000 | -71,798,000 | 456,554,000 | 36,507,000 | 420,047,000 | -67,470,000 |
| Dec 2023 | 151,000 | -45,550,000 | 4,180,000 | 130,867,000 | 169,241,000 | -38,374,000 | -38,723,000 |
| Dec 2022 | 0 | -27,967,000 | -27,676,000 | 36,119,000 | 80,320,000 | -44,201,000 | -23,303,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.94
Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)
max pain strike: $45.00 · spot: $38.92 · call volume: 10 · put volume: 248
Expected Move to 2027-01-15:
±$13.45
(34.56%) —
implied range
$25.47 –
$52.37
· ATM straddle on $39.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ZBIO | Zenas BioPharma, Inc. | $1.76B | $26.95 | — |
| XNCR | Xencor Inc | $1.77B | $23.80 | — |
| CMPS | COMPASS Pathways plc | $1.81B | $13.06 | — |
| ANIP | ANI PHARMACEUTICALS INC | $1.70B | $74.00 | — |
| NBTX | Nanobiotix S.A. | $1.69B | $33.31 | — |
News headlines (Yahoo Finance, 1h cache)
Septerna (SEPN) Heads To Healthcare Conferences, Is The Valuation Already Too Rich?
2026-09-14 14:10 · Yahoo
Septerna, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-09-10 20:00 · Yahoo
Septerna Appoints Industry Veteran Rajiv Patni, M.D., as Chief Medical Officer
2026-08-25 12:00 · Yahoo
Septerna, Inc. (SEPN) Reports Q2 Loss, Beats Revenue Estimates
2026-08-10 21:10 · Yahoo
Septerna's Chief People Officer Sold Nearly 12,000 Company Shares. What Does That Mean for Investors?
2026-07-05 13:55 · Yahoo
Is Septerna, Inc. (SEPN) Stock a Biotech Opportunity With a Potential First-in-Class Hypoparathyroidism Treatment?
2026-07-02 19:58 · Yahoo
Is Septerna a Stock to Sell After an Insider Let Go of 15,000 Shares?
2026-06-30 03:25 · Yahoo
Protego Biopharma Appoints Jae B. Kim, MD, as Chief Medical Officer
2026-06-08 11:00 · Yahoo
Party Time: Brokers Just Made Major Increases To Their Septerna, Inc. (NASDAQ:SEPN) Earnings Forecasts
2026-05-17 14:47 · Yahoo
Septerna Highlights Business Progress and Reports First Quarter 2026 Financial Results
2026-05-11 20:01 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.